Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 12/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.55 |
| ▸ | PIK3R1 | P27986 | 6/20 | 0.55 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | PRKDC | P78527 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.50 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15812966 | 1.00 | PIK3CG (0.55) | PIK3CGPIK3CBPIK3CDPIK3CAPIK3R1 | |
| SCHEMBL16345600 | 0.90 | PIK3CD (0.55) | PIK3CGPIK3CBPIK3CDPIK3CAPIK3R1 | |
| SCHEMBL20061285 | 0.90 | PIK3CG (0.57) | PIK3CGPIK3CBPIK3CDPIK3CAPIK3R1 | |
| SCHEMBL15812830 | 0.89 | PIK3CG (0.55) | PIK3CGPIK3CBPIK3CDPIK3CAPIK3R1 | |
| SCHEMBL15812829 | 0.89 | PIK3CG (0.55) | PIK3CGPIK3CBPIK3CDPIK3CAPIK3R1 | |
| SCHEMBL15812562 | 0.88 | PIK3CD (0.59) | PIK3CGPIK3CBPIK3CDPIK3CAPIK3R1 | |
| SCHEMBL15812564 | 0.88 | PIK3CD (0.59) | PIK3CGPIK3CBPIK3CDPIK3CAPIK3R1 | |
| SCHEMBL22854708 | 0.87 | PIK3CG (0.55) | PIK3CGPIK3CBPIK3CDPIK3CAPIK3R1 | |
| SCHEMBL22854766 | 0.87 | PIK3CG (0.55) | PIK3CGPIK3CBPIK3CDPIK3CAPIK3R1 | |
| SCHEMBL22854697 | 0.87 | PIK3CG (0.55) | PIK3CGPIK3CBPIK3CDPIK3CAPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3046563-B1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AS PI3-KINASE INHIBITORS | CALITOR SCIENCES LLC (US) | 2019-05-29 | — | — | EP | disclosed |
| EP-2935246-B1 | ISOQUINOLINONE OR QUINAZOLINONE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2018-07-25 | — | — | EP | disclosed |
| EP-2941426-B1 | SUBSTITUTED PYRIMIDINE AMINOALKYL-QUINAZOLONES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017130221-A1 | IMPROVED PROCESS FOR THE PREPARATION OF IDELALISIB | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-08-03 | — | — | WO | disclosed |
| US-9670194-B2 | Substituted aminopyrimidine compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9518046-B2 | Substituted aminopyrimidine compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160318913-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-11-03 | — | — | US | disclosed |
| CN-105924434-A | Substituted aminopyrimidine compound and usage method and application thereof | 广东东阳光药业有限公司 | 2016-09-07 | — | — | CN | disclosed |
| US-9266878-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD CALISTOGA LLC (US) | 2016-02-23 | — | — | US | disclosed |
| US-20160016915-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC. | 2016-01-21 | — | — | US | disclosed |
| US-20150218154-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2015-08-06 | — | — | US | disclosed |
| US-9029384-B2 | Phosphatidylinositol 3-kinase inhibitors | Gilead Calistoga, LLC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9018221-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD CALISTOGA, LLC (US) | 2015-04-28 | — | — | US | disclosed |
| CN-104513235-A | Substituted aminopyrimidine compound and use thereof | GUANGDONG HEC PHARMACEUTICAL | 2015-04-15 | — | — | CN | disclosed |
| US-20150087663-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-03-26 | — | — | US | disclosed |
| US-20140179673-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179718-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087663-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MYD88 | PIK3CG 5/4885PIK3CB 4/4885PIK3CD 2/4885 |
| US-20150218154-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, PIK3R5, PIK3R4 | PIK3CG 10/4885PIK3CB 12/4885PIK3CD 4/4885 |
| US-20140179673-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, PIK3R5, PIK3R4 | PIK3CG 10/4885PIK3CB 12/4885PIK3CD 4/4885 |
| US-20140179718-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3R5, PIK3CA, PIK3R4 | PIK3CG 10/4885PIK3CB 12/4885PIK3CD 5/4885 |
| US-20160318913-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MYD88 | PIK3CG 6/4885PIK3CB 4/4885PIK3CD 2/4885 |
| US-20160016915-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3R5, PIK3CA, PIK3R4 | PIK3CG 10/4885PIK3CB 12/4885PIK3CD 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.